Who is sponsoring NCT05385185?

NCT05385185 is sponsored by Hebei Medical University.

What drugs are being tested in NCT05385185?

Interventions in NCT05385185: Camrelizumab or envafolimab.

What condition does NCT05385185 study?

NCT05385185 studies Leptomeningeal Metastasis, Immune Checkpoint Inhibitor, Endostatin.

Is NCT05385185 still recruiting?

NCT05385185 is currently status unknown. Last updated 23 May 2022.

Last reviewed 2022-05-23 · How we verify

NCT05385185

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

Status unknown Phase 2 Last updated 23 May 2022

What this trial tests

Phase 2 trial testing Camrelizumab or envafolimab in Leptomeningeal Metastasis in 20 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
3 May 2024

3 December 2024

Quick facts

Lead sponsor	Hebei Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 May 2022
Primary completion	3 May 2024
Estimated completion	3 December 2024
Sites	1 location across China

Drugs / interventions tested

Camrelizumab or envafolimab — full drug profile →

Conditions studied

Leptomeningeal Metastasis — all drugs for Leptomeningeal Metastasis →
Immune Checkpoint Inhibitor — all drugs for Immune Checkpoint Inhibitor →
Endostatin — all drugs for Endostatin →

Sponsor

Hebei Medical University

Who can join

18 and older, any sex, with Leptomeningeal Metastasis or Immune Checkpoint Inhibitor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities.
Smith EC, Mott BT, Douglas E, Tatter SB, et al · · 2024 · cited 3× · PMID 39612029 · DOI 10.1007/s10555-024-10235-1

Verify or expand the search:

Other recruiting trials for Leptomeningeal Metastasis

Currently open trials in the same condition.

NCT07348965 — Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis · NA · recruiting
NCT07398599 — Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metast · NA · recruiting
NCT06296745 — Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. · Phase 2 · recruiting
NCT07098806 — Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases · Phase 1 · recruiting
NCT06984523 — Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomening · NA · active not recruiting

Other Hebei Medical University trials

Trials by the same sponsor.

NCT07304258 — A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cance · Phase 2 · not yet recruiting
NCT06934824 — Clinical Study of Double-Endoscopic Combined With Minimally Invasive Treatment for Early Gastric Cancer at Clinical Stag · NA · not yet recruiting
NCT06534814 — Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph · recruiting
NCT06201585 — Exploratory Study of Single-port Robot-assisted Gastrectomy · NA · unknown
NCT06073483 — Exploratory Study of Toumai Endoscopic Surgery System for Remote Gastrectomy · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05385185 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hebei Medical University
Last refreshed: 23 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05385185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing